BIOMAT Database Logo BIOMAT Database Logo

High-dose intravenous chelation therapy with deferoxamine. 1989

A Cohen, and J Mizanin, and E Schwartz
Division of Hematology, Children's Hospital of Philadelphia, Pennsylvania.

UI MeSH Term Description Entries
D007260 Infusion Pumps Fluid propulsion systems driven mechanically, electrically, or osmotically that are used to inject (or infuse) over time agents into a patient or experimental animal; used routinely in hospitals to maintain a patent intravenous line, to administer antineoplastic agents and other drugs in thromboembolism, heart disease, diabetes mellitus (INSULIN INFUSION SYSTEMS is also available), and other disorders. Drug Infusion Systems,Infusion Pump,Infusion Pumps, External,Infusors,Intravenous Drug Delivery System,Intravenous Drug Delivery Systems,Perfusion Pumps,Pumps, Infusion,Drug Infusion System,External Infusion Pump,External Infusion Pumps,Infusion Pump, External,Infusion System, Drug,Infusion Systems, Drug,Infusor,Perfusion Pump,Pump, External Infusion,Pump, Infusion,Pump, Perfusion,Pumps, External Infusion,Pumps, Perfusion,System, Drug Infusion,Systems, Drug Infusion
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D005293 Ferritins Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types. Basic Isoferritin,Ferritin,Isoferritin,Isoferritin, Basic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Cohen, and J Mizanin, and E Schwartz
Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia.
January 1985, Annals of the New York Academy of Sciences,
A Cohen, and J Mizanin, and E Schwartz
Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
January 1993, Bone marrow transplantation,
A Cohen, and J Mizanin, and E Schwartz
Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
April 1978, The Journal of pediatrics,
A Cohen, and J Mizanin, and E Schwartz
Indolent zygomycosis associated with deferoxamine chelation therapy.
January 1994, Mycoses,
A Cohen, and J Mizanin, and E Schwartz
Current status of iron chelation therapy with deferoxamine.
April 1990, Seminars in hematology,
A Cohen, and J Mizanin, and E Schwartz
Iron chelation therapy with deferoxamine in Cooley anemia.
April 1978, The Journal of pediatrics,
A Cohen, and J Mizanin, and E Schwartz
High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications.
January 2007, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit,
A Cohen, and J Mizanin, and E Schwartz
High-dose chelation therapy in thalassaemia.
February 1984, Lancet (London, England),
A Cohen, and J Mizanin, and E Schwartz
Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
February 2013, Blood cells, molecules & diseases,
A Cohen, and J Mizanin, and E Schwartz
Model-Based Optimisation of Deferoxamine Chelation Therapy.
February 2016, Pharmaceutical research,
Copied contents to your clipboard!